Literature DB >> 29462252

Toward optimizing outcomes in Her2-positive gastric cancer: timing and genomic context matter.

S J Klempner1, J Chao2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29462252     DOI: 10.1093/annonc/mdy066

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

1.  EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.

Authors:  Jorge A Carrasquillo; Maurizio Scaltriti; Nikolaus Schultz; Yelena Y Janjigian; Francisco Sanchez-Vega; Jaclyn F Hechtman; Pau Castel; Geoffrey Y Ku; Yaelle Tuvy; Helen Won; Christopher J Fong; Nancy Bouvier; Gouri J Nanjangud; Joanne Soong; Efsevia Vakiani; Mark Schattner; David P Kelsen; Robert A Lefkowitz; Karen Brown; Mario E Lacouture; Marinela Capanu; Marissa Mattar; Besnik Qeriqi; Fabiola Cecchi; Yuan Tian; Todd Hembrough; Rebecca J Nagy; Richard B Lanman; Steven M Larson; Neeta Pandit-Taskar; Heiko Schöder; Christine A Iacobuzio-Donahue; David H Ilson; Wolfgang A Weber; Michael F Berger; Elisa de Stanchina; Barry S Taylor; Jason S Lewis; David B Solit
Journal:  Cancer Discov       Date:  2018-11-21       Impact factor: 39.397

2.  FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.

Authors:  Samuel J Klempner; Russell Madison; Vivek Pujara; Jeffrey S Ross; Vincent A Miller; Siraj M Ali; Alexa B Schrock; Seung Tae Kim; Steven B Maron; Farshid Dayyani; Daniel V T Catenacci; Jeeyun Lee; Joseph Chao
Journal:  Oncologist       Date:  2019-06-27

3.  A Pilot Study of Baseline Spatial Genomic Heterogeneity in Primary Gastric Cancers Using Multi-Region Endoscopic Sampling.

Authors:  Joseph Chao; Jeeyun Lee; Kyung Kim; So Young Kang; Taehyang Lee; Kyoung-Mee Kim; Seung Tae Kim; Samuel J Klempner; Hyuk Lee
Journal:  Front Oncol       Date:  2020-02-25       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.